Economic information and modeling reportBudget impact model
Results
2 evidence topics · 3 sources
Tovecimig (CTX-009)
Second-line advanced biliary tract cancer
- Manufacturer
- Compass Therapeutics
- Regulatory submission
- BLA planned for the fourth quarter of 2026
- Launch
- Anticipated in 2027
- Last updated